Johnson & Johnson is scheduled to release its second quarter earnings report before the opening bell on Wednesday, July 15. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings of $2.85 per share, an increase from $2.77 per share in the year-ago period. The consensus estimate for revenue is $25.05 billion, compared to $23.74 billion reported last year.

On June 26, Johnson & Johnson announced additional data on IMAAVY throughout 12 abstracts at the European Academy of Neurology 2026 Congress. The company's shares rose 3.6% to close at $263.04 on Thursday.

Recent analyst activity indicates a positive outlook for the stock. Guggenheim analyst Vamil Divan maintained a Buy rating and raised the price target from $266 to $270 on June 26, 2026. Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $265 on May 13, 2026.

Other firms have also adjusted their targets. Barclays analyst Matt Miksic maintained an Equal-Weight rating and raised the price target from $234 to $255 on April 15, 2026. Stifel analyst Rick Wise maintained a Hold rating and raised the price target from $220 to $250 on the same date. Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and raised the price target from $240 to $263 on April 15, 2026.

Recent Analyst Ratings

Johnson & Johnson presented new data at the European Academy of Neurology (EAN) 2026 Congress demonstrating that IMAAVY (nipocalimab-aahu) provides sustained disease control in adults with generalized myasthenia gravis (gMG). Post-hoc analyses from the Phase 3 Vivacity-MG3 study revealed that the treatment significantly improved outcomes for patients early in their disease course and those with lower baseline symptom burden. The findings highlight the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression.

The analyses included adults with anti-acetylcholine receptor (anti-AChR) or anti-muscle-specific tyrosine kinase (anti-MuSK) antibody-positive gMG. In patients diagnosed within five years, IMAAVY plus standard of care (SOC) showed greater reductions in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores versus placebo plus SOC (-4.9 vs. -2.7) at Week 24. A greater proportion of patients receiving IMAAVY achieved sustained meaningful clinical improvement (MCI) for 20 weeks or more compared to placebo.

Clinical Efficacy and Safety

Patients with lower baseline symptom burden, defined as MG-ADL scores lower than 9, also experienced significant benefits. At Week 24, IMAAVY plus SOC decreased symptom severity and improved daily functioning compared to placebo plus SOC, with MG-ADL scores of -4.5 vs. -2.3. Additionally, Quantitative Myasthenia Gravis (QMG) reductions were greater with IMAAVY plus SOC (-5.2 vs. -1.9).

Data indicated that patients maintained control after contracting common infections. In the IMAAVY arm, observed symptom improvements were maintained within two weeks after patients contracted common infections, addressing a known cause of disease exacerbations in gMG.

Safety and tolerability were consistent across all patients in the study. The overall incidence of adverse events (AEs) was 84% in both the IMAAVY and placebo arms. Serious adverse events (SAEs) were reported in 9% of the IMAAVY arm compared to 14% in the placebo arm.

Ongoing Research and Study Design

Johnson & Johnson highlighted the innovative design of the PETUNIA study, intended to generate real-world safety data on pregnancy, maternal, and infant outcomes following exposure to IMAAVY during pregnancy. By leveraging prospective and retrospective reports, the study aims to capture detailed information in this setting to support clinical decision-making where current evidence is limited.

IMAAVY is an immunoselective neonatal Fc receptor (FcRn) blocker designed to target and reduce pathogenic IgG autoantibodies associated with gMG. It is currently approved for adult and pediatric patients (12 years of age and older) with anti-AChR or anti-MuSK antibody-positive gMG by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).